育心通胶囊对稳定性冠心病患者心肺适能疗效的多中心随机双盲安慰剂对照试验
该研究为多中心随机双盲安慰剂对照平行组试验,纳入404例稳定性冠心病患者,1:1分为育心通联合常规西药组与安慰剂联合常规西药组,治疗12周。结果显示育心通组无氧阈及SF-36一般健康、活力评分改善优于安慰剂组,但峰值摄氧量等其余指标无显著差异,不良事件相似。
要点
- 育心通胶囊辅助治疗12周可改善稳定性冠心病患者无氧阈。
- 育心通胶囊可提升SF-36一般健康和活力评分。
- 峰值摄氧量、代谢当量及心电图ST段压低指标无显著改善。
核心结论
- 育心通胶囊作为常规治疗的辅助疗法,可改善稳定性冠心病患者的无氧阈及SF-36一般健康和活力评分。
- 峰值摄氧量、代谢当量、心电图1-mm ST段压低持续时间和出现时间等指标的改善无统计学意义。
- 育心通组与安慰剂组不良事件相似。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照、平行组临床试验,在中国13家医院于2021年3月至2021年11月开展。
- 共404例稳定性冠心病患者按1:1随机分配接受育心通胶囊联合常规西药或安慰剂联合常规西药,疗程12周。
- 最终369例纳入分析,育心通组187例,安慰剂组182例。
主要发现
- 与安慰剂组相比,育心通组12周治疗后在无氧阈上显示改善(0.98 ± 2.88 vs. 0.12 ± 2.79 mL kg-1·min-1;LSMD 0.80 [95% CI: 0.28 to 1.32];P < 0.025)。
- 育心通组SF-36一般健康评分改善优于安慰剂组(13.61 ± 15.13 vs. 8.29 ± 14.14;LSMD 5.30 [95% CI: 2.33 to 8.31];P < 0.05)。
- 育心通组SF-36活力评分改善优于安慰剂组(12.46 ± 11.32 vs. 6.01 ± 11.41;LSMD 6.43 [95% CI: 4.13 to 8.31];P < 0.05)。
- 其他结局指标两组间无显著差异,不良事件相似。
关键数值与推荐
- 主要结局为峰值摄氧量和无氧阈;次要结局包括代谢当量、心电图1-mm ST段压低持续时间和出现时间、SF-36评分。
- 主要安全指标包括全血细胞计数、尿常规、肝功能、肾功能、凝血功能及12导联心电图,全程记录不良事件。
临床怎么用
- 对于稳定性冠心病患者,在常规西药治疗基础上可考虑联用育心通胶囊以改善无氧阈和部分生活质量评分。
- 育心通胶囊对峰值摄氧量等心肺运动试验核心指标未见显著获益,临床决策需结合个体情况。
局限性
- 原文未报告对峰值摄氧量等阴性结果的具体数值及统计量。
- 原文未报告样本量计算依据、盲法实施细节及试验注册号之外的方法学局限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Yuxintong capsule, a traditional Chinese patent medicine, has been widely used in the treatment of coronary heart disease (CHD). However, whether it can improve cardiopulmonary fitness (CRF) in patients with CHD remains unclear. AIM OF THE STUDY: To evaluate the efficacy and safety of Yuxintong capsule in CRF in patients with stable CHD. MATERIALS AND METHODS: A multicentre, randomized, double-blind, placebo-controlled, parallel-group trial was conducted in 13 hospitals in China from March 2021 to November 2021, and 404 patients with stable CHD were randomly assigned to receive either Yuxintong capsule and conventional Western medicine (Yuxintong group) or placebo and conventional Western medicine (placebo group) in a 1:1 ratio for 12 weeks (ChiCTR2000041293, December 23, 2020). The primary outcomes were peak oxygen uptake (VO2peak) and anaerobic threshold (AT). The secondary outcomes were metabolic equivalents (METs), duration and onset time of 1-mm ST-segment depression on electrocardiography (ECG), and 36-Item Short Form Health Survey (SF-36) scores. The main safety indicators included complete blood count, urinalysis, liver function, renal function, coagulation function, and 12-lead electrocardiogram. And adverse events were recorded throughout the trial. RESULTS: 369 patients, 187 in the Yuxintong group and 182 in the placebo group, were finally included for analysis. Compared with placebo group, 12-week treatment with Yuxintong showed an improvement in AT (0.98 ± 2.88 vs. 0.12 ± 2.79 mL kg-1·min-1; LSMD, 0.80 [95 % CI: 0.28 to 1.32]; P < 0.025), and general health (13.61 ± 15.13 vs. 8.29 ± 14.14; LSMD 5.30, [95 % CI: 2.33 to 8.31]; P < 0.05) and vitality scores (12.46 ± 11.32 vs. 6.01 ± 11.41; LSMD 6.43, [95 % CI: 4.13 to 8.31]; P < 0.05) on SF-36 scale. The other outcomes did not significantly differ between the two groups. The adverse events were similar between the two groups. CONCLUSIONS: Yuxintong capsule, as an adjunctive therapy to conventional treatment, improved AT, and general health and vitality scores on SF-36 scale in patients with stable CHD. However, the improvements in VO2peak, METs, and the duration and onset time of 1-mm ST-segment depression on ECG were not statistically significant.
引用
- Zheng L, Fu C, Song L, et al. Efficacy of Yuxintong capsule on cardiorespiratory fitness in patients with stable coronary heart disease: A multicentre, randomized, double-blind, placebo-controlled, parallel-group clinical trial. J Ethnopharmacol. 2026. PMID: 41500352. doi:10.1016/j.jep.2026.121169
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。